Loading...
Loading...
NUVL| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 65.2M |
| Operating I/L | -65.2M |
| Other Income/Expense | 8.2M |
| Interest Income | 8.2M |
| Pretax | -57.0M |
| Income Tax Expense | 0.2M |
| Net Income/Loss | -57.2M |
Nuvalent, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for cancer patients. Their lead product candidates include NVL-520, a brain-penetrant ROS1-selective inhibitor, and NVL-655, a brain-penetrant ALK-selective inhibitor. These products are designed to address treatment resistance and central nervous system-related adverse events, providing potential solutions for patients with brain metastases. The company generates revenue through the development and potential commercialization of these innovative therapies, aiming to meet the unmet medical needs of cancer patients.
